Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Service Revenue		$ 1,400,000		$ 1,740,855
Operating expenses:
Research and development	956,814	482,142	2,513,486	794,141
General and administrative	2,807,398	904,018	3,288,607	3,583,168
Total operating expenses	3,764,212	1,386,160	5,802,093	4,377,309
Loss from operations	(3,764,212)	13,840	(5,802,093)	(2,636,454)
Other expense:
Interest expense, net	(433,979)	(137,089)	(954,886)	(1,283,794)
Change in fair value of derivative on debt	630,174	746,809	93,829	10,512
Loss on debt conversion		(41,469)	(27,504)	(166,067)
Total other expense	196,195	568,251	(888,561)	(1,439,349)
Net loss before non-controlling interests	(3,568,017)	582,091	(6,690,654)	(4,075,803)
Net loss attributable to non-controlling interests	(336,737)		(656,294)
Net income (loss) attributable to Oncotelic Therapeutics, Inc.	$ (3,231,280)	$ 582,091	$ (6,034,360)	$ (4,075,803)
Basic net loss per share attributable to common stock	$ (0.01)	$ 0.01	$ (0.03)	$ (0.05)
Basic weighted average common stock outstanding	369,547,235	88,152,403	232,700,641	86,537,199
Diluted net loss per share attributable to common stock	$ (0.01)	$ 0.01	$ (0.03)	$ (0.05)
Diluted weighted average common stock outstanding	369,547,235	94,736,703	232,700,641	86,537,217